Home › Cancro al rene (carcinoma a cellule renali) › Nebraska › Omaha
Studi clinici su Cancro al rene (carcinoma a cellule renali) a Omaha, NE
12 studi su Cancro al rene (carcinoma a cellule renali) cercano partecipanti presso sedi a Omaha e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
In reclutamentoFase 1
- Research Site, Omaha
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
In reclutamentoFase 1
- NEO-811 Omaha Site, Omaha
A Phase 1 Study of the Safety and Tolerability of CTX-10726
In reclutamentoFase 1
- Nebraska Cancer Specialists, Omaha
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #2, Omaha
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
In reclutamentoFase 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · a 9 mi di distanza
A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma
In reclutamentoFase 1
- Research site, Omaha
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
In reclutamentoFase 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · a 9 mi di distanza
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
In reclutamentoFase 1
- The University of Nebraska Medical Center, Omaha
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
In reclutamentoFase 3
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131), Omaha
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
In reclutamentoFase 1/2
- Nebraska Cancer Specialists, Omaha
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
In reclutamentoFase 3
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- Oncology Associates PC, Omaha
Studi su Cancro al rene (carcinoma a cellule renali) in altre città
- Houston, TX35 studi
- New York City, NY27 studi
- Nashville, TN23 studi
- Dallas, TX23 studi
- St. Louis, MO23 studi
- Los Angeles, CA20 studi
- Boston, MA16 studi
- Baldwin Park, CA16 studi
- Pittsburgh, PA15 studi
- Philadelphia, PA15 studi
- Queens, NY15 studi
- Cleveland, OH14 studi
Altri studi a Omaha
- Cancro alla prostata27 studi
- Cancro del polmone non a piccole cellule24 studi
- Cancro al seno22 studi
- Cancro (tutti i tipi)18 studi
- Cancro colorettale18 studi
- Mieloma multiplo16 studi
- Cancro ovarico14 studi
- Linfoma non Hodgkin14 studi
- Cancro pancreatico14 studi
- Cancro metastatico13 studi
- Carcinoma a cellule squamose della testa e del collo13 studi
- Insufficienza cardiaca13 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.